New imaging technology called fluorescence lifetime (FLT) imaging improves the accuracy of cancer surgery for multiple tumour types.
List view / Grid view
US researchers develop a dual-action cell therapy engineered to eliminate established tumours and train the immune system to eradicate primary tumour and prevent cancer’s recurrence.
Scientists have synthesised a new molecule that could kill a broad spectrum of hard-to-treat cancers, including triple-negative breast cancer, by exploiting a weakness in cells not previously targeted by other drugs.
Researchers have been able to slow down the progression of glioblastoma in mice, the most common adult brain cancer.
The new study looked at the network of gene-gene interactions associated with cancer onset and progression to identify therapeutic targets.
The RNA-modifying protein METTL1 could be targeted to treat some types of aggressive cancers, including brain, blood and kidney.
Having synthesised the curcusone D compound, researchers demonstrated its promise as the first BRAT1 inhibitor, making it a potential cancer therapy.
Researchers have shown how increased YTHDF3 expression correlates with brain cancer metastases, making it a target for the condition.
The first comprehensive survey of genomics, transcriptomics, global proteomics and phosphoproteomics has revealed insights into paediatric brain tumours.
In pre-clinical studies, researchers have shown that a new therapy called POMHEX can destroy brain cancer cells that were missing one of two genes encoding the enolase enzyme.
Using CRISPR to cut out fusion genes, scientists were able to specifically induce cancer cell death in murine models of sarcoma and leukaemia.
The Brain Metastasis Cell Lines Panel compiles research from various international institutions on the numerous brain metastasis cell lines that have been developed, in hopes collaboration will expedite research and drug development.
Researchers demonstrated NSPP completely prevented cognitive decline in mice treated with radiation for patient-derived glioblastomas.
Researchers demonstrated that ABCC4 is essential to signalling in the SHH subgroup of medulloblastomas and when expression was reduced in mice, the tumours shrank.
Research into the structure of the drug-integrin complex has enabled the creation of drugs which inhibit integrin as effectively as currently used compounds, without causing excessive bleeding.